Start with your question. Search first, choose the closest subject and keep personal details private. Posting guidelines
Notifications
Clear all
Nootropics & Cognitive Enhancement
2
Posts
2
Users
0
Reactions
297
Views
Topic starter
25/08/2022 4:58 pm
Meta-level question: how do you evaluate evidence for oxiracetam when the human data is thin and most trials are small?
The comparison group matters more than the compound when the outcome is something as fuzzy as focus.
The animal data is stronger than the human data and the human data is not nothing, it is just small.
Two weeks is not enough time to attribute anything to a compound unless the effect is dramatic.
Vivid dreams are reported widely and are not in the label because there is not really a label.
Where does the human data stop and the extrapolation start?
25/08/2022 5:45 pm
Baseline first.